论文部分内容阅读
本研究旨在探讨初治多发性骨髓瘤(MM)患者血清IL-6的预后价值。回顾性分析238例MM患者初诊时血清IL-6水平,比较不同IL-6水平患者的临床特点以及与疾病预后的关系。结果表明,血清IL-6水平大于100 pg/ml的MM患者,其ECOG评分大于3患者比例、MBD 2-4级患者比例、血肌酐水平明显高于IL-6水平小于100 pg/ml的MM患者。两组在年龄、核型异常比例、FISH检测13号染色体缺失者比例、血磷水平、低血钙患者比例、血清β2-MG水平、CD138+/CD38+细胞比例以及血清Hb、CRP、Alb、LDH水平、治疗反应等均无明显差异。血清IL-6水平小于100 pg/ml组以及大于100 pg/ml组的疾病进展时间(TTP)分别为:23个月、14个月(P=1.93);两组的总体生存时间(OS)分别为:35个月、29个月(P=0.04)。结论:不同IL-6水平患者的临床特点及疾病预后具有明显差异。在临床实践中,应用放射性免疫的方法检测初诊患者血清IL-6水平可作为MM患者的常规检查,可有效地提示患者的病情及预后。
The purpose of this study was to investigate the prognostic value of serum IL-6 in patients with newly diagnosed multiple myeloma (MM). The serum level of IL-6 in 238 patients with MM was analyzed retrospectively. The clinical characteristics of patients with different levels of IL-6 and the relationship with the prognosis were compared. The results showed that patients with MM with serum IL-6 levels above 100 pg / ml had ECOG scores greater than 3, MBD with grade 2-4, and serum creatinine levels significantly higher than MM with IL-6 levels less than 100 pg / ml patient. Serum levels of β2-MG, CD138 + / CD38 + cells, serum Hb, CRP, Alb and LDH levels in the two groups were analyzed in terms of age and karyotype abnormalities, FISH detection of chromosome 13 deletion, , No significant difference in response to treatment. The time to progression (TTP) of serum IL-6 levels of less than 100 pg / ml and greater than 100 pg / ml were 23 months and 14 months respectively (P = 1.93). The overall survival time (OS) Respectively: 35 months, 29 months (P = 0.04). Conclusion: The clinical features and prognosis of patients with different levels of IL-6 have significant differences. In clinical practice, the application of radioimmunoassay detection of newly diagnosed patients serum IL-6 levels can be used as a routine examination of MM patients, which can effectively prompt the patient’s condition and prognosis.